Sun Pharmaceutical Industries Ltd (SUN.NS)
** Shares of Sun Pharmaceutical Industries rise as much as 1.65 pct in early trade, but down 0.5 pct as of 0552 GMT
MUMBAI, June 8 India's Sun Pharmaceutical Industries Ltd said on Wednesday it had entered the dermatology segment as part of an initiative to further expand its retail offerings.
To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_06012016.pdf FACTORS TO WATCH 10:30 am: Federal cabinet likely to meet in New Delhi. Agenda not given. GMF: ASIA LIVECHAT - MARKETS FOCUS with Michael Every, Head of Financial Markets Research-Asia-Pacific, Rabobank Lots happening in Asia. While China seems to have cooled down a bit, we have the the BOJ piling on suprises nearly every policy meet. Also
MUMBAI India's Sun Pharmaceutical Industries Ltd issued a weaker-than expected annual sales outlook as it grapples with increased competition in the United States as well as supply constraints, sending its shares 5 percent lower.
MUMBAI, May 31 India's largest drugmaker Sun Pharmaceutical Industries Ltd reported a near-doubling in fourth-quarter profit, although that missed analysts' estimates as weakness in emerging markets outweighed higher sales in India and the United States.
** India's largest drugmaker says it received a subpoena from the U.S. Department of Justice seeking information about the pricing and marketing of generic drugs it sells in the country
** India's Sun Pharmaceuticals rises as much as 2.44 pct, set to close higher after two straight days of losses
MUMBAI Indian stocks fell more than 1 percent on Monday, posting their biggest single-day fall in five weeks, as investors booked profit in recent outperformers ahead of a busy week of events, including the expiry of domestic derivative contracts.
MUMBAI, March 28 Indian shares fell 1 percent on Monday as investors booked profit in recent outperformers such as State Bank of India and Hindalco Industries ahead of a busy week of events, including the release of U.S. economic data and the expiry of domestic derivative contracts.
* Dilip Shanghvi says not looking for external assets as of now Further company coverage: